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Disease or trauma-induced loss or dysfunction of neurons in any central nervous system (CNS) tissue will have 
a significant impact on the health of the affected patient. The retina is a multilayered tissue that originates from 
the neuroectoderm, much like the brain and spinal cord. While sight is not required for life, neurodegeneration-
related loss of vision not only affects the quality of life for the patient but also has societal implications in 
terms of health care expenditure. Thus, it is essential to develop effective strategies to repair the retina and 
prevent disease symptoms. To address this need, multiple techniques have been investigated for their efficacy 
in treating retinal degeneration. Recent advances in cell transplantation (CT) techniques in preclinical, animal, 
and in vitro culture studies, including further evaluation of endogenous retinal stem cells and the differentia-
tion of exogenous adult stem cells into various retinal cell types, suggest that this may be the most appropriate 
option to replace lost retinal neurons. Unfortunately, the various limitations of CT, such as immune rejection or 
aberrant cell behavior, have largely prevented this technique from becoming a widely used clinical treatment 
option. In parallel with the advances in CT methodology, the use of electrical stimulation (ES) to treat retinal 
degeneration has also been recently evaluated with promising results. In this review, we propose that ES could 
be used to enhance CT therapy, whereby electrical impulses can be applied to the retina to control both native 
and transplanted stem cell behavior/survival in order to circumvent the limitations associated with retinal CT. 
To highlight the benefits of this dual treatment, we have briefly outlined the recent developments and limita-
tions of CT with regard to its use in the ocular environment, followed by a brief description of retinal ES, as 
well as described their combined use in other CNS tissues.
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INTRODUCTION
The vast majority of cells in the human body are 
programmed to perform specialized functions, having 
unique morphological, functional, and electrical proper-
ties. This is also true for cells in the ocular environment, 
including those of the retina. The mammalian retina con-
tains five groups of neurons responsible for transmitting 
light signals to the brain: photoreceptor cells (cones and 
rods), bipolar cells, horizontal cells, amacrine cells, and 
retinal ganglion cells (RGCs). These cells are supported 
by the Müller cells, which are the primary immune cells 
in the retinal environment along with retinal microglia. 
Furthermore, the retinal pigmented epithelium (RPE), a 
monolayer of cells located between the photoreceptor cells 
and Bruch’s membrane, forms the blood–retinal barrier 
in addition to metabolically supporting other processes, 
950 MANTHEY ET AL.
including phagocytosis of photoreceptor outer segments 
and secretion of various trophic factors1. During disease 
or following traumatic injury, any number of these spe-
cialized cells of the retina can be damaged or lost, result-
ing in varying levels of retinal degeneration and decreased 
visual acuity.
Although the mechanisms underlying retinal degenera-
tion are distinct for each disease, they invariably involve 
the irreversible loss of retinal neurons, neuronal connec-
tions, and/or supporting glia2. For example, glaucoma 
involves the selective loss of RGCs, while photoreceptor 
loss is common during retinitis pigmentosa (RP)3. Age-
related macular degeneration (AMD), on the other hand, 
involves degeneration of the RPE as well as photoreceptor 
cell death4. To date, there are currently no singularly reli-
able clinical treatment options to completely halt or reverse 
the loss of vision associated with these diseases. However, 
a number of novel techniques are currently being evalu-
ated for their potential therapeutic use in the treatment of 
retinal degeneration, including gene therapy, optogenetics, 
electrical stimulation (ES), cell transplantation (CT), etc.
In this review, we have focused on the treatment of 
several prominent retinal diseases, including AMD, RP, 
traumatic optic neuropathy (TON), nonarterial ischemic 
optic neuropathy (NAION), and retinal artery occlusion 
(RAO). Basic descriptions of these diseases can be found 
in Figure 1. Once neuronal degradation has occurred, 
it is essential that these cells and synaptic connections be 
replaced in order to restore vision to the patient, making 
CT one of the most attractive treatment options. However, 
the application of CT methods in the retina comes with a 
number of limitations. Thus, we hypothesize that a dual 
therapeutic approach should be adopted utilizing ES to 
augment CT to treat retinal degeneration. While this the-
ory has never been tested in the retina, it is supported by 
various studies in other tissues, highlighting the additive 
benefits of the two techniques, whereby CT can be used 
to replace lost cells and/or provide trophic support, while 
ES can be utilized to stimulate and protect the remaining 
endogenous cells in addition to facilitating function in the 
transplanted cells. Together, we believe these treatments 
provide the highest possibility for improvement in visual 
Figure 1. General descriptions of various retinal degenerative diseases, including age-related macular degeneration (AMD), retinitis pig-
mentosa (RP), traumatic optic neuropathy (TON), nonarterial ischemic optic neuropathy (NAION), and retinal artery occlu sion (RAO).
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acuity following retinal degeneration or trauma. In this 
review, we begin our analysis by first discussing current 
CT techniques and their limitations along with a brief his-
tory of ES, followed by an evaluation of their combined 
therapy in other tissues emphasizing the potential appli-
cations in the retina.
EVALUATION OF CURRENT RETINAL CELL 
TRANSPLANTATION METHODOLOGIES
CT involves the replacement of dead or abnormal cells 
with healthy cells that mimic their normal function and 
behavior. Thus, in retinal degenerative diseases, cells 
must be replaced with the specific cell type lost, namely, 
the photoreceptor cells, RPE, and/or RGCs. While trans-
plantation of sheets or suspensions/aggregates of retinal 
cells is feasible to some extent, the level of integration 
of these cells appears to be largely dependent on the age 
of the donor/host, quality of the transplanted cells, and 
the type of retinal degradation involved, as highlighted 
by experiments performed in various disease models5–21, 
thus limiting their effectiveness. Further, developing fetal 
retinal cells have also been investigated for their use in 
retinal CT techniques with some success8. However, a 
large quantity of these postmitotic cells is required, the 
collection of which also poses ethical issues. In fact, 
many research groups have turned to use of adult stem 
cells in clinical and laboratory settings in order to avoid 
these ethical concerns and enhance the level of cellular 
integration into the retina.
Stem cells are cells that have the potential to develop 
into many other cell types and can be used to replace 
cells that are lost, damaged, or altered during disease 
or trauma. Although the term “stem cell” has been used 
variably since 1906 when Alexander Maximow developed 
his theory of hematopoiesis22,23, it was not until 1981 that 
murine embryonic stem cells (ESCs) were isolated24,25. 
Further, it was another 17 years before Thomson et al.26 
isolated human ESCs and developed the first human 
embryonic culture stem cell lines. Since their discovery, 
researchers worldwide have sought to understand stem 
cell behavior, morphology, and function. Notably, the 
three essential characteristics of these cells are that they 
are unspecialized, self-renewing, and potent. The level 
of stem cell potency, or the range of cell types they can 
differentiate into, may vary depending on the age of the 
organism at isolation. For example, totipotent stem cells, 
which can differentiate into all cell types found in both 
embryonic and extraembryonic tissues, are typically derived 
from cells in the first 4 days following fertilization of the 
egg in mammals (up to approximately the 16-cell stage), 
while pluripotent (giving rise to all embryonic cell types) 
and multipotent stem cells (giving rise to cells of a spe-
cific germ layer) can be found later in development as 
well as in some adult tissues, including the eye27.
Endogenous Retinal Stem Cells for Transplantation
The retina develops from the neural tube and, while 
morphologically unique, is classified as a central ner-
vous system (CNS) tissue. Although somatic stem cells 
are present in most tissues, being largely found in clus-
ters known as niches, endogenous adult retinal stem 
cells have been difficult to identify. A large proportion 
of the ocular regeneration literature is focused on fish 
and amphibian models28–30, which utilize a type of intrin-
sic retinal regeneration that does not occur in mammals. 
However, these studies have led to the identification of 
three primary types of endogenous adult retinal cells that 
have been evaluated for transplantation in various spe-
cies: Müller cells31–38, RPE cells39,40, and ciliary pigmented 
epithelial (CPE) cells41–43 (Fig. 2A). While there is some 
controversy as to the specific stem cell nature of these 
cells44,45, there is evidence indicating that they can differ-
entiate into retinal cell types under certain conditions. In 
fact, Müller cells appear to primarily differentiate into cone 
and rod photoreceptors31–33,46–48 as well as RGCs27, while 
CPE and RPE cells have the potential to differentiate into 
rod or cone photoreceptor-like cells, respectively45,49–54. 
During the transplantation/retinal regeneration process, 
these cell types would need to undergo several cellular 
actions, including dedifferentiation, proliferation, migra-
tion, neural differentiation, and functional integration55. 
Interestingly, subretinal or intravitreal injection of Müller 
cells derived from humans leads to migration of the trans-
planted cells into the retinal parenchyma and expression 
of neuronal cell markers31, while transplantation of CPE 
or RPE cells has been performed with varying levels 
of success56.
Notably, the use of CPE or similar progenitor cells in 
the iris57–60 could, in theory, be isolated from the affected 
patient, limiting issues with immune rejection. However, 
caution should be exercised if the patient’s particular 
retinal disease has a genetic component. In contrast, 
autologous CT using Müller glia from the patient’s ret-
ina is not feasible, necessitating the use of donor cells47. 
Preparation and transplantation of postmitotic RPE cells 
or sheets from a donor, while possible, involve a signifi-
cant amount of tissue and may also be associated with a 
higher level of surgical risk61. To circumvent these issues, 
recent research has described methodologies using non-
retinal stem cell-derived RPE cells, photoreceptors, and 
RGCs that may, in some aspects, provide additional 
advantages over endogenous ocular cells, such as low-
ering the chances of immune rejection and providing an 
unlimited number of donor cells62–67.
Exogenous Stem Cells for Retinal Transplantation
Various types of nonretinal stem cells have been studied 
for their use in retinal CT (Fig. 2B). This includes neural 
stem cells (NSCs), which have been employed for neural 
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and glial cell replacement in spinal cord and brain inju-
ries68–70 and function to protect the photoreceptors in the 
damaged retina via their phagocytotic capabilities to elim-
inate the photoreceptor outer segments—a role typically 
performed by the RPE—and the secretion of neurotrophic 
factors71–73. Mesenchymal stem cells (MSCs), which can 
be derived from bone marrow (BM-MSCs)74,75, adipose 
tissue (ADSCs)76, or dental pulp (DPSCs)77, appear to 
play a trophic support role via the secretion of factors that 
stimulate endogenous cells78–80. Finally, ESCs81,82, from 
the inner cell mass of the blastocyst, and induced pluri-
potent stem cells (iPSCs), which can be reprogrammed 
from adult fibroblasts and somatic cells via retroviral 
transduction62,83, have been used to replace photoreceptor 
cells, RPE cells, and all other cells of the retina15,84–86.
Recent research suggests that in order to increase inte-
gration and function of retinal cells derived from nonreti-
nal stem cells, regardless of origin, they should first be 
differentiated in vitro prior to transplantation8. BM-MSCs, 
for example, have been observed to differentiate into both 
RPE cells and photoreceptors when cocultured with RPE 
cells in vitro87, but show no evidence of differentiation 
into mature retinal cells after direct transplantation despite 
integration into the retina74. Thus, it seems that while 
BM-MSCs may play a neuroprotective role when trans-
planted, differentiation into retinal cell types before trans-
plantation is essential if these cells are being used to replace 
the lost or abnormal cells. Interestingly, human ESCs can 
be differentiated into retinal cells in serum-free culture 
media supplemented with a mixture of noggin, dickkopf-
related protein 1 (DKK-1), insulin-like growth factor 1 
(IGF-1), and basic fibroblast growth factor (bFGF)82. 
Similar techniques also work for iPSCs using specific 
combinations of growth factors63,86. Differentiation into 
retinal neurons was also enhanced when cocultured with 
mouse retinas from photoreceptor-degenerated mice. For 
a full review of ESC/iPSC reprogramming and retinal dif-
ferentiation/transplantation protocols, please see Reynolds 
and Lamba88, Borooah et al.85, and Wright et al.89.
Importantly, the transcriptome/proteome of these cells 
should ideally mimic that of the native cells they are replac-
ing. In doing so, the likelihood of these cells interacting 
appropriately with the neighboring healthy cells may 
increase. To this end, Lamba and Reh90 have published 
genomic profiling data comparing human ESC-derived 
retinal cells to fetal human retinal cells and showed that 
the expression of retinal genes between the two subsets 
of cells are strongly correlated. Thus, it appears that these 
ESC-derived cells adopt similar gene expression as that 
utilized during retinal development. iPSCs, on the other 
hand, have their own distinct expression profile, highlight-
ing some potential differences91. However, regardless of 
gene expression, the transplanted cells ultimately need to 
behave as the native cells would. This includes integrat-
ing into the correct retinal layer and forming functional 
synapses, which are essential to improving visual acuity. 
This has been shown to occur when using human ESC-
derived retinal cells following subretinal transplantation 
in adult wild-type mice, whereby the transplanted photo-
receptor cells migrated into the outer nuclear layer and 
extended outer segments15. In this same study, there was 
also evidence of neuroprotection on the surrounding host 
cells when transplanted into a light-damage model as well 
as functional responses to light using electroretinography 
(ERG) after transplantation in blind Crx−/− mice15, which 
display photoreceptor degeneration92. iPSC-derived pho-
toreceptor cells transplanted into the subretinal space 
also integrated into the correct retinal layer and increased 
visual function86.
While further research is necessary to determine the 
optimal transplantation conditions, the use of CT to treat 
retinal degenerative diseases, using endogenous or exog-
enous stem cells, is an interesting avenue of regenerative 
medicine. Notably, a number of clinical trials, as previ-
ously highlighted by Mead et al.93, and animal studies using 
exogenous stem cells to treat retinal diseases are ongoing.
Limitations of Cell Transplantation-Based 
Retinal Therapies
Although various cell types have been tried for reti-
nal CT, very few have had reliable success. Furthermore, 
the methods and analyses used in retinal CT studies are 
often variable and require optimization. The limitations 
of each cell type, whether endogenous or exogenous, as 
FACING PAGE
Figure 2. Cell transplantation cell types and basic approaches. (A) Endogenous retinal stem cells: Müller cells, retinal pigmented 
epithelial (RPE) cells, and ciliary pigmented epithelial (CPE) cells. Following transplantation, Müller cells have been shown to dif-
ferentiate into both rod and cone photoreceptors as well as retinal ganglion cells (RGCs), while RPE and CPE cells differentiate into 
cone and rod photoreceptors, respectively. (B) Exogenous retinal stem cells: neural stem cells (NSCs; isolated from the brain), mes-
enchymal stem cells (MSCs; isolated from bone marrow, adipose tissue, and dental pulp), embryonic stem cells (ESCs; isolated from 
the inner cell mass at the blastocyst stage), and induced pluripotent stem cells (iPSCs; isolated adult fibroblasts/somatic cells that are 
reprogrammed using retroviral transduction). Stem cells are isolated and cultured in vitro. While these multipotent/pluripotent cells 
have been directly transplanted into the eye, higher levels of integration and functional restoration have been observed when the cells 
are differentiated into a retinal cell type prior to transplantation. This is particularly important if the stem cells are being used to replace 
degraded photoreceptors, RGCs, or RPE cells. The image of the hematoxylin and eosin-stained mouse eye was obtained using a light 
microscope (Carl Zeiss, Jena, Germany) using a 10´ objective.
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well as the quality of these cells before transfer also need 
to be weighed when determining what cell type and trans-
plantation method (e.g., intravitreal injection, subretinal 
transplantation) to apply. In terms of results, ESCs seem 
to be a feasible option for retinal CT; however, the ethi-
cal issues surrounding their isolation hinder their clini-
cal use. Thus, the use of differentiated iPSCs may be the 
most advantageous nonretinal donor source for CT to 
replace neurons following retinal degeneration as well 
as for disease modeling, testing therapeutic efficacy, and 
drug discovery64.
An additional limitation to consider when assess-
ing the cell type for retinal CT is the possible effects of 
using autologous stem cells from a subject with a genetic 
retinal disease. While using cells from the patient may 
limit immune system-related complications, it may also 
be necessary to “correct” the genetic defects in the cells 
prior to transplantation or risk the possible reoccurrence 
of the disease. This type of genetic correction has been 
performed previously to repair the mutation responsible 
for gyrate atrophy, which affects the RPE and leads to 
photoreceptor cell loss94. However, the cost and effort 
required to produce and test gene-corrected cells are cur-
rently high. Alternatively, donor stem cells with a simi-
lar human leukocyte antigen (HLA) type can be used95. 
In some diseases involving multiple genetic risk fac-
tors and/or cellular aging specific to retinal tissue (e.g., 
AMD), it may be unnecessary to correct these genetic 
defects as the reprogramming process may restore a level 
of cellular youth.
Other limitations concerning the use of retinal CT stem 
from the plasticity of the transplanted cells (including the 
level of differentiation prior to and/or after transplanta-
tion) as well as the habitability of the host environment. 
For example, in the ocular environment, while Müller 
cell proliferation is required during retinal regeneration, 
this process of reactive gliosis can also result in scar tis-
sue formation that may hinder integration of the trans-
planted cells55. To circumvent this issue, it is possible to 
disrupt the outer limiting membrane formed by the acti-
vated Müller cells in order to increase cellular integration 
following transplantation96. Indeed, West et al.97 demon-
strated that immune suppression (using cyclosporine A 
treatment to reduce the T-cell-mediated immune response) 
increased the number of transplanted photoreceptor cells 
from 76 ± 20 cells per eye in the unsuppressed animals 
to 275 ± 89 cells per eye at 4 months posttransplantation, 
highlighting a significant change in the long-term sur-
vival of these cells. However, it would be ideal to avoid 
the need for pharmacological disruption of the already 
fragile diseased retina.
Furthermore, cell death-induced activation of reti-
nal microglia is another common feature observed in 
genetic models of various retinal diseases98,99 as well as 
injury-induced retinal degeneration100,101, and this acti-
vation may lead to the secretion of various cytokines 
and neurotoxins that can further injure the surrounding 
neurons102–104. Protection of the retinal neurons appears to 
be largely modulated by the expression of neurotrophic 
growth factors secreted by microglia/Müller cells, such 
as IGF-1, ciliary neurotrophic factor (CNTF), etc.100,105, 
many of which appear to be altered after injury106. 
Although the eye, including the subretinal space, is con-
sidered an immune-privileged site, when ocular integrity 
is compromised, macrophage invasion and immune acti-
vation can result in rejection of the transplanted cells107. 
Furthermore, it is currently unclear if an internal retinal 
microglial-mediated inflammatory response could act to 
hinder integration or function of the transplanted cells. 
These issues with immune rejection are common follow-
ing CT in a number of tissues. In fact, it is important to 
avoid xenogenic factors (including animal serum, patho-
gens, and non-human-derived reagents) during culture 
and differentiation that may cause immune rejection after 
transplantation. While a chemical-based culture system108 
as well as animal serum/contamination-free culture con-
ditions109–112 have been implemented for generating reti-
nal cells from human ESCs and iPSCs, immune rejection 
still poses a significant issue during retinal CT. Even if 
the process is successful and the cells are not rejected by 
the host, there are limited data indicating that the trans-
planted cells establish the functional synapses required 
for the restoration of visual function112. Notably, recent 
literature has suggested that a more habitable native cell 
environment, allowing the transplanted cells to integrate 
and form synapses, can be facilitated using ES.
HISTORY AND TYPES OF ELECTRICAL 
STIMULATION IN THE RETINA
ES is a technique that uses an electrical current to 
activate nerves and restore function. Recent applica-
tions of ES in the field of neuroscience include both 
high-intensity and low-intensity ES currents, otherwise 
known as “functional ES,” and have been used to treat 
Parkinson’s disease113,114 and other neurodegenerative dis-
eases115. Historically, the application of ES can be traced 
to 1791, when Galvani discovered that the leg muscles 
of a dead frog twitched when treated with an electri-
cal spark. In ophthalmology, ES has a long history dat-
ing back as early as 1873, when Dor used complicated 
machines to treat “amblyopia and amauroses,” “retino-
choroiditis with pigment infiltration,” and “glaucoma and 
white optic atrophy”116. Furthermore, during normal ocu-
lar development, electrical waves are transmitted across 
the retina via neuronal action potentials. A study in 2002 
by Morimoto et al.117, which demonstrated improved sur-
vival of transected RGCs in rats following ES, appears to 
be the first report that ES can mediate neuroprotection. 
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Since then, various studies have been performed to further 
evaluate the neuroprotective effect of ES both in vitro and 
in vivo, using cell culture, human trials, and animal mod-
els. Please see Sehic et al.118 for an excellent review of the 
most recent animal and clinical studies using ES.
Types of Ocular Electrical Stimulation
There are four types of ES commonly used in oph-
thalmology: subretinal ES (SES), optic nerve stump ES, 
transcorneal ES (TcES), and whole-eye ES (WES) (Fig. 3). 
In SES, a microphotodiode array is implanted in the sub-
retinal space, and stimulation is applied directly to the 
retina. This type of ES has been widely used with retinal 
implants, which provide the patient with low-resolution 
images by stimulating the surviving retinal cells119,120. 
Alternatively, ES of the optic nerve stump uses a pair of 
electrodes attached to the end of the nerve to stimulate 
function, while TcES utilizes a contact lens containing 
both the active and reference electrodes directly on the 
cornea, making it much less invasive. WES generates 
an electrical current that goes through the entire eye, 
whereby one electrode is placed at either the cornea or 
the orbit, while the reference electrode is placed on the 
skin, in the mouth, or elsewhere in the body. The elec-
trical current then passes through other tissues before 
reaching and stimulating the retina. Thus, the intensity 
may need to be higher for WES compared to other types 
of ES that come in direct contact with the ocular environ-
ment. WES includes techniques such as transorbital ES 
and transcranial alternating current stimulation (tACS). 
Figure 3. Schematic diagrams highlighting various types of electrical stimulation (ES) in the ocular environment, including subretinal 
ES, optic nerve stump ES, transcorneal ES, and whole-eye ES. Subretinal ES involves implantation of a microphotodiode array in 
the subretinal space, whereby the electrical current is directly applied to the retina. Optic nerve stump ES utilizes a pair of electrodes 
attached to the end of the optic nerve to stimulate function. Transcorneal ES is performed via a contact lens electrode along the surface 
of the cornea. In general, whole-eye ES involves the placement of one electrode at the cornea or orbit (gray dot) and the reference 
electrode elsewhere on the skin, body, or in the mouth, as shown here (black dot). Eye diagram obtained and edited from the National 
Eye Institute at the National Institutes of Health.
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A number of studies have been conducted utilizing these 
various types of ES, with TcES currently being the 
most common118.
Notably, while the published ES studies discussed 
in the present review primarily focus on stimulation of 
endogenous retinal function, retinal prostheses that func-
tion to fully or partially replace the native retina and/or 
other segments of the visual system, including the optic 
nerve, lateral geniculate nucleus, and visual cortex, have 
also been evaluated. Ultimately these devices all seek 
to restore vision by artificially activating the electri-
cal responses in each of these locations. In the retina, 
a number of epiretinal, subretinal, and suprachoroidal 
prostheses have been developed, with varying levels of 
success. Furthermore, optogenetics, which utilizes gene 
transfer of light-sensitive proteins into retinal neurons, is 
another emerging avenue of study regarding vision loss. 
While an in-depth discussion of these techniques and 
devices is beyond the scope of this review, please refer to 
these recent publications by Yue et al.121, Fernandez and 
Normann122, and Lewis et al.123 for an all-encompassing 
assessment of the current progress in these fields.
Regardless of the type of ES utilized, whether SES, 
optic nerve stump ES, TcES, or WES, very few, if any, 
detrimental side effects have been reported for the sub-
ject during or after treatment. In general, it appears that 
ES treatment does in fact enhance the survival of neu-
ronal retinal cells in various ophthalmic disease models 
through various mechanisms or, at the very least, does 
not hinder vision further. Moreover, the direct and indi-
rect effects of ES on the retinal cells could also similarly 
affect transplanted cells in the ocular environment. We 
therefore propose a combination approach utilizing ES 
to enhance CT techniques to treat disease- or trauma- 
related visual deficits.
APPLICATION OF ELECTRICAL STIMULATION 
TO ENHANCE CELL TRANSPLANTATION 
THERAPIES FOR RETINAL DISEASES
Loss of vision not only affects the quality of life for 
the patient but also has societal implications in regard to 
their level of productivity and overall health care expen-
diture. Thus, it is essential to develop effective strate-
gies for retinal cell survival, repair, and replacement for 
various neurodegenerative diseases affecting the retina. 
Fundamentally, our proposed combination of ES and CT 
techniques focuses on the use of electrical manipulation 
to control both native and transplanted stem cell behavior 
in order to bypass some of the common limitations asso-
ciated with CT. For use in treating retinal degenerative 
diseases, ES-CT treatment addresses four main issues: 
native cell survival, transplanted cell survival, transplan-
ted cell integration, and functional synapse formation/
axon regeneration (Fig. 4).
The recent advances in the field of retinal ES imply 
that this technique could be used as a pretreatment to 
modulate retinal cell function, essentially priming the 
host environment for the introduction of transplanted 
cells. In order to elucidate the comprehensive mecha-
nism of ES on the retina, a whole genome-wide expres-
sion profile of TcES-treated wild-type Brown Norway 
rats was performed using quantitative real-time PCR124. 
The results indicate that 490 genes were differentially 
expressed in TcES-treated rats compared to untreated 
rats 4 h after application and included changes in various 
genes associated with potential neuroprotective cell func-
tions. For example, the authors observed a significant 
downregulation in the expression of various proapoptotic 
genes such as B-cell lymphoma 2-associated X (Bax) 
and members of the tumor necrosis factor (TNF) fam-
ily. Furthermore, no negative effects on the structure 
and function of the retina were observed in the rats up to 
35 h after TcES treatment. Ciavatta et al.125, on the other 
hand, focused their investigation on the specific expres-
sion of growth factors in the retinas of Royal College of 
Surgeons (RCS) rats, a widely used model of RP, after 
SES using a microphotodiode array. In doing so, they 
found a consistent, significant elevation in the expression 
of FGF2 (also known as bFGF), suggesting that this par-
ticular growth factor may participate in the local neuro-
protection induced by ES.
Focusing on the effects of ES on retinal neuronal cells, 
Henrich-Noack et al.126 used an optic nerve crush animal 
model to test the effects of TcES treatment immediately 
after injury and on postinjury day 11. They found that 
compared to sham-treated controls, there was a higher 
percentage of surviving RGCs in the TcES group. TcES 
also delayed posttraumatic cell death significantly and 
decreased optic nerve crush-associated neuronal swelling 
as well as shrinkage, especially in RGCs. It is likely that 
this ES-mediated protection of the retinal neurons would 
apply to both endogenous and transplanted neuronal cells 
as it appears to be primarily related to the expression of 
neurotrophins, including brain-derived neurotrophic fac-
tor (BDNF), IGF-1, CNTF, etc., and injection of these 
factors appears to increase neuronal survival in several 
retinal injury models127,128.
Various effects have also been observed following 
ES treatment via the modulation of Müller and micro-
glial cell changes. For example, it has been demonstrated 
that ES regulates neurotrophic factors and the levels of 
various enzymes in retinal Müller cells. In fact, in a study 
evaluating the neuroprotective effect of TcES on an ani-
mal model of ischemic retinal damage, Wang et al.129 
quantified glutamine synthetase (GS) expression, which 
appears to be significantly increased following treatment. 
The morphology and function of the retina were also pre-
served in treated animals, indicating that the protection 
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against ischemic insults mediated by TcES is possibly 
related to attenuated glutamate excitotoxicity in Müller 
cells. Sato et al.130 also found that after applying ES to 
cultured retinal Müller cells, the mRNA level of IGF-1 
increased significantly and largely depended on the Ca2+ 
influx through L-type voltage-dependent calcium chan-
nels (L-VDCCs). Upregulation of IGF-1 was also found 
in optic nerve crush and optic nerve transection models 
after TcES131,132. In a previous study, ES was observed 
to increase the mRNA and intracellular protein levels of 
Figure 4. Barriers to the integration and functionality of transplanted retinal stem cells and their possible mediation via subsequent 
treatment with ES. (A) Activation of Müller cells can result in reactive gliosis, whereby cells will proliferate and form scar tissue 
blocking the outer limiting membrane, hindering cellular integration beyond this layer. Application of ES after cell transplantation 
may decrease the levels of aberrant glial cell proliferation and immune function, thus allowing the transplanted cells to migrate to the 
correct layer in the retina. (B) Activation of retinal microglial cells can lead to the secretion of various cytokines and neurotoxins that 
can further injure the surrounding cells, both endogenous and transplanted. ES could be used to limit the detrimental effects of the 
microglia cells by stimulating them to secrete trophic factors that will support cell survival. (C) Even if transplantation is successful 
and the cells migrate and integrate properly, it is still possible that the transplanted cells will be rejected by the tissue and attacked by 
the immune system in an attempt to expel the “foreign” cells. The chance of immune rejection is increased if xenogeneic factors are 
used to cultivate the transplanted cells or if ocular integrity, and therefore the immune privileged nature of the eye, is compromised. 
The use of ES prior to immune rejection could help increase the chances of transplanted cell survival. (D) Finally, following successful 
transplantation, functional synapses are also required if vision is to be restored. It is possible that migration, orientation, and growth, 
including synapse formation, of the transplanted cells could be enhanced using subsequent ES. The image of the hematoxylin and 
eosin-stained murine retinal section was obtained using a light microscope (Carl Zeiss) using a 40´ objective.
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BDNF in cultured retinal Müller cells, while its extracel-
lular expression remained unchanged133. Moreover, the 
L-VDCC blocker, nifedipine, has been shown to sup-
press this ES-induced increase in BDNF mRNA expres-
sion. These results indicate that ES of Müller cells could 
upregulate endogenous BDNF levels in the retina, and 
this upregulation may be dependent on L-VDCCs. In sup-
port of this theory, Zhou et al.134 found a positive regula-
tory effect of ES on the production of BDNF and CNTF 
in Müller cells, and also provided evidence that BDNF 
rather than CNTF may play a major role in the promo-
tion of Müller cell-induced photoreceptor cell survival. 
Finally, in a recent proteomic study135, TcES performed 
on wild-type adult Wistar rats was shown to significantly 
alter the expression of 25 proteins. These proteins appear 
to play various functions (e.g., cellular signaling, syn-
aptic transmission, metabolism, immune function, and 
structural maintenance) and included several suspected 
retinal regeneration factors, such as epidermal growth 
factor receptor (EGFR), prohibitin, tenascin-X, etc. Inter-
estingly, IGF-1, BDNF, and FGF-2 were surprisingly 
absent from this list, a discrepancy the authors believe 
is related to their experiments being conducted on wild-
type retinas versus a degenerative model135, similar to a 
previous study reporting changes in the transcriptome124. 
Thus, it can be hypothesized that ES treatment may alter 
the secretion of these neurotrophic factors, resulting in a 
more balanced and less hostile environment.
In addition to changes in neuronal and Müller cells, ES 
has also been shown to influence retinal microglia. In fact, 
Zhou et al.134 found that ES can significantly decrease the 
number of activated microglia cells with ameboid shapes 
when cocultured with light-damaged 661W cells (light-
reared cone-derived cells). This decrease was also associ-
ated with changes in the secretion of the proinflammatory 
cytokines interleukin-1b (IL-1b) and TNF-a by the micro-
glial cells. In this same study, it was also apparent that 
ES treatment had no direct effect, positive or negative, 
on the survival of the photoreceptor cells themselves, but 
rather the functional changes are solely mediated by the 
effects of ES on surrounding microglia and Müller cells. 
Previous research also suggests that interactions between 
microglia and Müller glial cells in vivo may contribute to 
the overall effects of ES on the retina100.
The expression of essential neurotrophic factors and 
altered Müller/microglial cell function not only appear to 
help keep the native retinal cells (and possibly the trans-
planted retinal stem cells) alive but also promote vary-
ing levels of axon growth136. In this study, Goldberg et al. 
showed that increasing electrical activity and prolonging 
cellular depolarization potentiate the observed BDNF-
induced axon growth via increasing cAMP levels. It is 
therefore possible that ES can enhance axonal function 
as well as regulate the immune environment in the native 
retinal cells. Similar effects on axon formation could also 
occur in the transplanted cells themselves.
The direct effects of ES performed before, during, or 
after CT on the transplanted cells have not been evalu-
ated in the retina but have been investigated in studies 
performed using this type of combination therapy in other 
CNS-derived tissue injuries, such as brain and spinal cord 
traumas. For example, in a study using a spinal cord injury 
model in rats, transplanted BM-MSCs were subsequently 
subjected to ES, which resulted in significantly enhanced 
locomotor function, increased survival (31.3 ± 4.6% com-
pared to 26.7 ± 2.5% in unstimulated transplants), dif-
ferentiation, and integration of the transplanted cells as 
well as increased axonal regeneration, as determined by 
enhanced somatosensory-evoked potentials137. It should 
also be noted that this previous study utilized an implant-
able ES device, which can be equated to similar devices 
used for retinal implantation. Furthermore, Matsumoto et 
al.138 have demonstrated that pretreating BM-MSCs with 
ES in vitro prior to transplantation resulted in an increase 
in neural markers at day 7 [nestin and paired box pro-
tein 6 (Pax6)] as well as day 14 [neurofilament heavy 
(NF-H) and microtubule-associated protein 2 (MAP2)] 
in culture. Furthermore, the expression of neurogenin 2 
(Ngn2), a protein associated with neural differentiation, 
and b-catenin, a mediator of cell survival, proliferation, 
and differentiation, was also increased on culture day 7 
in the ES-treated cells. When these 7-day-old stimulated 
cells were transplanted into C57BL/6 mice with traumatic 
brain injury, the authors observed a higher percentage of 
transplanted cells expressing neural markers after stimu-
lation along with enhanced neuronal differentiation and 
significantly improved motor function, as highlighted by 
rotarod (performed on days 14 and 28) and beam walk-
ing (performed on day 28) tests ( p < 0.01 in both com-
pared to the control animals). The mammalian retina also 
expresses both Ngn2139 and b-catenin140. Ngn2 appears to 
regulate the expression of the atonal homolog 5 (ATH5) 
and, thus, the downstream expression of the b3 subunit 
of a neuronal nicotinic acetycholine receptor141, which is 
a specific marker of RGC specification during retinogen-
esis142. b-Catenin signaling, on the other hand, plays an 
essential role in modulating the effects of various growth 
factors and cytokines during retinal regeneration after 
injury143,144 as well as during development, affecting the 
expression of a number of genes involved in chromatin 
organization, neurogenesis, and cell motion/migration145. 
It is, therefore, possible that treating cells with ES prior 
to or during retinal transplantation could also affect the 
expression of these genes in a manner that would aid sur-
vival, differentiation, and function after CT.
Similar to these results concerning spinal cord and 
traumatic brain injury, ES-enhanced CT has also been 
observed during muscle reinnervation after sciatic injury 
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using transplanted neurons146 and myocardial regenera-
tion following ischemic heart failure147, the latter of which 
appears to occur via stimulation and production of exo-
somes containing cardioprotective molecules148. Notably, 
exosomes are also utilized for cell–cell communication 
in the normal and diseased retina149–152 and confer differ-
ent biological effects depending on their host cell. For 
example, using a laser-induced choroidal neovasculariza-
tion model, Hajrasouliha et al.149 demonstrated that reti-
nal astrocytes produce exosomes that contain factors that 
suppress vessel leakage and inhibit neovascularization, 
while exosomes released from the RPE do not mediate 
these changes. In fact, it is possible that exosomes may 
play a critical role in ES-induced changes in chorioretinal 
blood flow observed after treatment153. In this study by 
Kurimoto et al.153, which investigated the chorioretinal 
blood flow in 10 healthy subjects before and after TcES 
in different retinal areas using laser speckle flowgraphy, 
TcES was shown to induce an increase in chorioretinal 
blood flow in the area around the macula and midway 
between the optic disc and macula, but not around the 
optic disc itself. Indeed, blood flow rapidly increased in 
the first 30 min after TcES, peaked at 24 h, and decreased 
gradually by 40 h after treatment. This is consistent 
with the observed increase in IGF-1, a known effector 
of vasodilation154–157, in retinal Müller cells130–132, which 
are themselves known to regulate retinal blood flow via 
the secretion of growth factors158. While the full mecha-
nism underlying how TcES leads to this increase in cho-
rioretinal blood flow remains unclear, it is possible that 
endosomes play a significant role. It also seems plausible 
that treatment with ES may not only alter the contents of 
these exosomes but may also induce their production in 
both the transplanted cells as well as the remaining reti-
nal cells. These changes could have a significant effect 
on cell communication and the transfer of materials (e.g., 
proteins, mRNA, miRNA, etc.), leading to greater inte-
gration of the exogenous cells, protection of the surviving 
endogenous cells, and enhanced visual function. Thus, 
additional research investigating exosome function after 
ES-CT treatment is warranted.
It should be noted that the basis of the direct behav-
ioral response of the stem cells to ES is not altogether 
surprising as neurons are known for their quick depolar-
ization in response to electrical changes159. In fact, ES has 
been shown to promote neurite outgrowth during normal 
developmental differentiation160–165 as well as guide the 
growth direction of regenerating nerve fibers166–168. ES 
also appears to be capable of inducing the differentiation 
of ESCs169, BM-MSCs138, and ADSCs170 into neurons in 
culture with or without simultaneous gene therapy. Thus, 
the dual application of stem cell therapy and a controllable 
electrical current may provide a novel mechanism to real-
ize the full advantages of CT therapies for retinal repair.
Taken together, it is likely that the utilization of ES-CT 
combination therapy to treat retinal degenerative diseases 
will have two primary benefits: (1) increased trophic sup-
port by the remaining endogenous retinal cells resulting 
in improved habitability of the host environment and 
(2) enhanced differentiation, integration, and synapse for-
mation of the transplanted stem cells and remaining endog-
enous neurons. It is also possible that increased cell–cell 
communication via exosome production could function as 
a feedback loop between the indirect and direct effects on 
the immune response and transplanted cells, respectively. 
Optimization of ES-CT combination therapy in future 
studies should focus on the type and timing of ES (e.g., as 
a pretreatment, simultaneous, or post-CT) as well as the 
ideal cell type for transplantation under these conditions. 
Additional investigations should also be performed to 
evaluate other experimental and evaluation parameters.
CONCLUSION
The eye has various characteristics that make it an 
ideal organ system to study regeneration, including unique 
immune properties, isolation from other organs, easy 
surgical accessibility, well-understood anatomy and phys-
iology, and convenience of imaging and functional moni-
toring. Further, while vision is one of our most important 
senses, it is not essential to life, permitting continued 
study of the tissue following complications and/or failed 
treatment. The eye is also a paired structure in vertebrates, 
which allows comparison to the contralateral eye during 
treatment in a single organism.
The retina is an essential component of the visual 
axis and is also susceptible to a number of degenera-
tive diseases involving photoreceptor, RGC, and/or RPE 
cell death or dysfunction. It is imperative that effective 
treatment options to replace and stimulate these cells be 
developed for clinical use. While both ES and CT have 
beneficial effects when used as individual courses of 
treatment, studies in a number of other CNS tissues sug-
gest that they may have additive advantages when ES is 
used to augment CT.
In the present review, we have outlined the basic con-
cepts, mechanisms, and limitations of CT as well as a brief 
history of ES in the hopes that future research into their 
optimization and combined use will enhance their effec-
tiveness in treating retinal degenerative diseases. The cur-
rent literature describing ES-CT combination methods in 
other cellular contexts provides an excellent foundation 
for future investigations in the retina. Ongoing research 
in this field will be paramount to the prevention and cure 
of retinal degenerative diseases.
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